Understanding the determinants of resistance of 5-fluorouracil (5FU) is of significant value to optimising administration of the drug, and introducing novel agents and treatment strategies. Here, the expression of 92 genes involved in 5FU transport, metabolism, co-factor (folate) metabolism and downstream effects was measured by realtime PCR low density arrays in 14 patient-derived colorectal cancer xenografts characterised for 5FU resistance. Candidate gene function was tested by siRNA and uridine modulation, and immunoblotting, apoptosis and cell cycle analysis. Predictive significance was tested by immunohistochemistry of tumours from 125 stage III colorectal cancer patients treated with and without 5FU. Of 8 genes significantly differentially expressed between 5FU sensitive and resistant xenograft tumours, CTPS2 was the gene with the highest probability of differential expression (p=0.008). Reduction of CTPS2 expression by siRNA increased the resistance of colorectal cancer cell lines DLD1 and LS174T to 5FU and its analogue, FUDR. CTPS2 siRNA significantly reduced cell S-phase accumulation and apoptosis following 5FU treatment. Exposure of cells to uridine, a precursor to the CTPS2 substrate uridine triphosphate, also increased 5FU resistance. Patients with low CTPS2 did not gain a survival benefit from 5FU treatment (p=0.072), while those with high expression did (p=0.003). Low CTPS2 expression may be a rationally-based determinant of 5FU resistance. 
Introduction
The development of molecular-targeted agents in cancer treatment has led to an accumulation of novel agents for testing in the clinic. 1, 2 The introduction of novel agents usually occurs, however, only in the context of failure of more established regimens. 3 In this context, the antimetabolite, 5-fluorouracil (5FU), is of significant interest. Today, 5FU remains one of the most commonly administered agents for cancer chemotherapy. 1, 4 In addition, it is a baseline component of many first-line regimens in many cancer types, including colorectal, gastric, lung, breast and skin cancer. Understanding the determinants of resistance of 5FU therefore holds significant value to optimising administration of the drug, and the introduction of novel agents and treatment strategies.
Over the years, numerous determinants of 5FU resistance have been identified, with the most prominent being genes and proteins involved in the metabolism and activity of the drug. [5] [6] [7] [8] These have included thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), methylene tetrahydrofolate reductase and p53 for which many different features (gene variants, RNA and protein levels, and protein activity) of these enzymes have been found to associate with different patient outcomes from 5FU treatment in a manner consistent with their roles in 5FU metabolism. These findings are exemplified by a landmark report by Salonga et al. 9 , in which patients resistant to 5FU treatment were observed to have high expression levels of at least one of TS, TP or DPD. This study highlighted the sensitivity of investigating pathway components of 5FU metabolism, and well as the relevance of RNA levels as 5FU determinants.
Genome-wide gene expression profiling studies have been performed in various cancer cell line [10] [11] [12] and tumour xenograft 13 models of 5FU sensitivity and resistance.
More than 420 candidates have been identified by these studies, with the pathways implicated including those involved in DNA replication and repair, and protein processing and targeting. However, the candidate determinants identified in these studies have yet to gain any prominence, presumably due in part to the difficulty in rationalizing their relevance to 5FU activity. Another reason has been the lack of functional and clinical validation in independent samples series.
Cytotoxicity from 5FU is attributed to three mechanisms resulting from its anabolism: (1) inhibition of TS interfering with nucleotide pools, (2) incorporation into DNA, and (3) incorporation into RNA (Fig. 1 ). 4 Methylene tetrahydrofolate is an important co-factor in TS inhibition, implicating folate metabolism as an important factor in 5FU activity. Catabolism of 5FU is linked to its clearance, for which DPD is the initial and rate-limiting enzyme. All these processes involve numerous genes and proteins, of which only a minority have been investigated for their association with 5FU resistance. 14 To gain further insight into 5FU resistance, this study was undertaken to characterise determinants of 5FU resistance through real-time PCR analysis of 5FU pathway-based genes in colorectal tumour xenografts characterised for their resistance to 5FU.
Results
The overall expression of 5FU pathway genes associates with 5FU resistance in colorectal tumour xenografts Unsupervised hierarchical clustering of the expression of the 92 5FU pathway genes in the 14 xenograft samples was performed to assess whether an association existed between 5FU pathway gene expression overall and 5FU resistance,. The clustering distinctly separated sensitive and resistant tumours (Fig. 2) , supportive of an association. Three groups were identified, of which 1 group (III, consisting of 1 sample) appeared to be an outlier and was not considered further. The other two groups (I and II) differed significantly in the proportion of tumours resistant to 5FU (0/4, 0% vs 2/9, 22% respectively, p<0.05).
CTPS2 is the top candidate gene differentially expressed between 5FU resistant and sensitive tumour xenografts
In supervised analysis, expression of 8 (CTPS2, SLC28A2, ITPA, NME6, ENTPD5, MLH1, PARP1, UCK1) of the 92 genes examined were significantly different (p<0.05) between 5FU-sensitive and 5FU-resistant tumour xenografts (Supplementary Table S2 ).
SLC28A2 was higher in resistant tumours, while the other 7 genes were expressed at lower levels. Cytidine triphosphate synthase type 2 (CTPS2) had the highest probability to be differentially expressed (p=0.008), and hence was selected for further analysis. Thirteen colorectal cancer cell lines (listed in Supplementary Table S1 ) were screened for their IC 50 to identify suitable models to test the effects of CTPS2 suppression on 5FU sensitivity. DLD1 and LS174T cells were the most sensitive (IC 50 = 2.1 ± 0.2µM and 2.0 ± 0.3µM, respectively), and hence were chosen for subsequent experiments. DLD1 and LS174T also differ in p53 mutation status (mutant and wild-type respectively) 11 that is known to influence 5FU sensitivity. Basal gene and protein levels of CTPS2 in the cell line panel did not correlate with 5FU sensitivity (data not shown).
CTPS2 suppression increases resistance to 5FU and FUDR
To verify the efficiency and characterise the timecourse of suppression of CTPS2 by CTPS2 siRNA, DLD1 cells were transfected with CTPS2 siRNA or controls and monitored for 120 hours. Doubling time were assessed and found not to be significantly different for negative control (20h) and CTPS2 silenced (22h) DLD1 cells (p = 0.5) (data not shown). Loss of CTPS2 protein expression was observed for 96 hours following exposure to CTPS2 siRNA but not controls. CTPS2 expression was restored in CTPS2 siRNA-transfected cells after 120 hours exposure (Fig. 3A) . DLD1 cells were then transfected with CTPS2 siRNA or controls and their IC 50 values calculated 72 hours after 5FU exposure (96h post-siRNA transfection). A significant (p<0.05) 15 to 20-fold increase in the IC 50 was observed in CTPS2-silenced cells (74 ± 38µM) compared to cells transfected with negative control siRNA (5.1 ± 1.2µM) and transfection reagent alone (3.8 ± 0.5µM) (Fig. 3B ). CTPS2 siRNA also conferred an approximately 28-fold increased resistance to 5FU in the LS174T cell line compared to controls (p <0.05) (data not shown).
The effect of CTPS2 suppression on sensitivity to FUDR was also evaluated in DLD1 cells. CTPS2 siRNA-treated cells showed an increased IC 50 for FUDR (15 ± 5.5µM) compared to cells transfected with negative control siRNA (3.0 ± 0.6µM) (p=0.04) and transfection reagent alone (2.3 ± 0.04µM) (p=0.02), although the effect was not as profound as for 5FU (Fig. 3C ).
CTPS2 suppression reduces S-phase accumulation and apoptosis in cells after 5FU treatment
DLD1 cells treated with CTPS2 or negative control siRNA were exposed for 24 hours to 5µM or 70µM 5FU, corresponding to the IC 50 of cells transfected with negative control or CTPS2 siRNA respectively. The higher concentration of 5FU resulted in marked S phase accumulation of cells transfected with the negative control, consistent with the mechanism of action of 5FU (Fig. 4A) . In contrast, the cell cycle phase distribution of DLD1 cells transfected with CTPS2 siRNA was similar to that of controls. Exposure to 70µM 5FU for 24 hours also markedly increased the formation of nucleosomes in cells transfected with negative control compared to cells transfected with CTPS2 siRNA (Fig.   4B ). Similar effects were not observed in cells treated with the lower concentration (5µM) of 5FU.
Excess extracellular uridine, mimicking reduced CTPS2, confers resistance to 5FU
CTPS2 is the rate-limiting enzyme in the synthesis of cytosine nucleotides, catalyzing the formation of CTP from UTP. 15 Incorporation of the 5FU anabolite, FUTP, into RNA is a major mechanism of 5FU cytotoxicity. 4 We therefore hypothesized that the association between low CTPS2 levels and 5FU resistance may be due to the accumulation of UTP that competes and reduces FUTP incorporation into RNA. We therefore mimicked reduced CTPS2 levels in DLD1 cells by culturing them in the presence of 1mM uridine (precursor of UTP) prior to the addition of 5FU. In support of the hypothesis, cells exposed to 1mM uridine showed an approximately 6-fold increase in the IC 50 for 5FU (32.8 ± 1.2µM) compared to cells grown in the absence of this nucleotide (5.0 ± 0.9 µM) (p= 0.04).
CTPS2 siRNA does not sensitise DLD1 cells to a selective TS inhibitor, raltitrexed
To further establish the role of CTPS2 in promoting 5FU-mediated cell death through the RNA incorporation pathway, the IC 50 of a selective TS inhibitor raltitrexed 16 17 was measured in DLD1 cells transfected with or without CTPS2 siRNA. There was no significant change in the IC 50 of raltitrexed in the presence of CTPS2 siRNA (1.2 ± 0.055µM) or negative control siRNA (1.6 ± 0.073µM) (p = 0.9).
Patients with high CTPS2 levels gained a survival benefit from 5FU treatment, while those with low levels did not Table S3 ). To investigate the predictive significance of CTPS2, the differences in survival between patients treated with and without 5FU in subgroups of CTPS2 positive and negative stage III colorectal cancer patients were examined. In CTPS2 positive patients, 5FU treatment was associated with a
Discussion
In this study, we examined the expression of 92 genes involved in 5FU metabolism, transport, activity and folate metabolism in 14 patient-derived colorectal tumour xenografts by real-time PCR LDA in order to gain further insight into 5FU resistance.
The pathway-based approach was chosen to optimize the number of genes assessed and the likelihood that candidates identified could be rationalized for their function. The pathways examined were selected on the basis that most of the prominent determinants of 5FU resistance are components of these pathways. 14 The choice to analyze gene expression derived from the numerous reports linking gene expression to 5FU resistance. 5, 9, 18, 19 Analysis by real-time PCR LDA was selected to maximize the precision and dynamic range of analysis, 20 and obviated the need for real-time PCR validation required in hybridization array studies. In support of this approach, the overall expression patterns of the pathway genes analyzed in this study distinctly separated xenograft tumours that were sensitive and resistant to 5FU in unsupervised clustering (Fig. 1) .
Of the 92 genes examined, CTPS2 had the highest probability (p=0.008) of being differentially expressed between sensitive and resistant tumours, and hence was selected as the optimal candidate for further investigation. In functional studies, suppression of CTPS2 by siRNA markedly increased resistance to 5FU in IC 50 studies (Fig. 3) , consistent with the association of low CTPS2 expression with 5FU resistance, observed in xenograft models. The increase was observed in two cell lines, suggesting the changes were not cell-specific. The cell lines also differed in their TP53 mutation status (Supplementary Table S1 ), reducing the likelihood these mutations were a major factor in the changes in resistance. Suppression of CTPS2 also increased resistance to the 5FU analogue, FUDR, indicating the association was not restricted to 5FU, and was applicable to other fluoropyrimdines.
To further verify the functional link between CTPS2 and 5FU, the effect of CTPS2 suppression was examined on the known hallmarks of 5FU cytotoxicity of cell cycle S-phase accumulation and apoptosis. 4 Suppression of CTPS2 by siRNA reduced Sphase accumulation and diminished apoptosis (Fig. 4) , consistent with the association of low CTPS2 levels and 5FU resistance. These results, taken together with the IC 50 findings, support both a phenotypic and mechanistic role for CTPS2 expression in determining 5FU cytotoxicity.
CTPS2 encodes an isoform of CTP synthetase (CTPS), which is the rate limiting enzyme in the synthesis of cytosine nucleotides required for RNA and DNA synthesis. 21 In humans, an equally active isoform is encoded by CTPS, although the dominant isoform in normal and malignant cells is unclear. 22 In rationalizing the link between low CTPS2 levels and 5FU resistance, one possible explanation was that the reduced rate of CTPS2 results in accumulation of UTP. This in turn leads to competition with the 5FU anabolite, FUTP, for incorporation into RNA, thereby reducing biochemical errors that would normally cause cells to accumulate in S-phase and commit them to apoptosis. This hypothesis was tested in this study by simulating UTP accumulation through the addition of excess extracellular uridine. In support of the hypothesis, the addition of uridine rendered sensitive DLD1 cells resistant to 5FU, at the same time reinforcing the contribution of RNA incorporation in 5FU cytoxoticity. Indeed, Peters et al showed that 1mM uridine inhibited the incorporation 5FU into RNA, thus reversing the growth inhibitory effect of 5FU, in WiDR colorectal cancer cells. 23 Decreased expression of UMP kinase was also reported to increase 5FU resistance in colorectal cancer cells due to impaired incorporation of FUTP into RNA. 24 Furthermore, silencing CTPS2 in DLD1 cells had no apparent effect on sensitivity of raltitrexed, which does not influence the RNA-mediated cytotoxicity, thereby providing additional support of involvement of the RNA pathway.
A lack of reports on the relationship between 5FU resistance and CTPS2 makes it difficult to gain further insight into mechanisms of actions. Whelan et al. showed that treatment of CHO cells with UV radiation and ethylmethanesulfonate generated mutations in CTPS that altered its synthase activity and increased the intracellular pools of CTP and dCTP. 25 Interestingly, these mutations in highly conserved regions of CTPS were also associated with resistance to 5FU. However, these results are on CTPS mutations and not CTPS2 expression, and are in a different cellular context, so caution needs to be exercised in their interpretation.
To verify the clinical relevance of CTPS2 expression, we examined tissue samples from 444 colorectal cancer patients treated with and without 5FU chemotherapy for the predictive significance of CTPS2 stained immunohistochemically. Consistent with the xenograft and in-vitro findings associating low CTPS2 expression and 5FU resistance, patients with high CTPS2 expression gained a survival benefit from 5FU (p=0.003), while those with low levels did not (p=0.072). Nevertheless, these results should be treated with caution given the latter association almost reached statistical significance.
Moreover, an imbalance in age between patients treated and not treated with 5FU chemotherapy in this non-trial sample series suggests these observations should only be considered to be of a preliminary nature.
Materials and Methods

Tumour Xenografts
Samples of 14 colorectal tumour xenografts characterised previously for 5FU resistance 27 were obtained from the Max-Delbrück-Center for Molecular Medicine (Berlin-Buch, Germany). With resistance defined as less than 50% tumour shrinkage after drug treatment for 40 days, 6 xenografts were sensitive and 8 resistant to 5FU.
Cell lines
Thirteen colorectal cancer cell lines (listed in Supplementary Table S1) 
Primary Tumour Samples
Tissue array blocks constructed previously, 
Compounds
The cytotoxic drugs 5FU, FUDR and raltitrexed were obtained commercially (Sigma).
All stock solutions were prepared in DMSO (MP Biomedical, Solon, OH) at a final concentration in culture media of 0.25% (v/v).
Gene expression analysis
A total of 92 genes (displayed in Fig. 1 and listed in Supplementary Table S2 ) involved in the metabolism, transport, activity and co-factor (folate) metabolism of 5FU were identified from the Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway database (http://www.genome.ad.jp/kegg/pathway.html) and literature review. Total RNA was extracted from tumour xenografts using TRI reagent (MRC, Cincinnati, OH, USA) according to the manufacturer's instructions. RNA yields and purity were determined spectrophotometrically at 260 and 280nm using the Nanodrop 2000 (Thermo Scientific, Wilmington, DE). RNA quantification from low density arrays was performed by real-time PCR analysis according to manufacturer's instructions.
Briefly, 1µg of total RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit. The reaction mixtures were incubated at 25°C for 10 min, followed by 37°C for 120 min and 95°C for 5 min. Subsequently, 9µl of cDNA sample containing 400ng of total RNA along with 41µl of nuclease-free water and 50µl of PCR master mix (2x) were loaded into each sample port on the low density array. The array was centrifuged twice for 1 min at 331 x g at room temperature and then sealed. Realtime PCR was performed using an ABI PRISM 7900 HT Sequence Detection System.
Relative quantification was performed according to the ΔΔCt method, 30 with GAPDH used as the reference gene to normalize for loading, and the COLO201 cell line as a calibrator sample.
Inhibition by small interfering RNA (siRNA)
Pre-designed Silencer Select siRNA (CTPS2, sense strand: 5'-GGU UCG AGG UAA ACC CUA ATT-3' and antisense strand: 5'-UUA GGG UUU ACC UCG AAC CGA-3'; Negative Controls, sense strand: 5'-UAA CGA CGC GAC GAC GUA ATT-3' and antisense strand: 5'-UUA CGU CGU CGC GUC GUU ATT-3') were purchased from Applied Biosystems. To minimize off-target effects, all sequences were BLAST-searched against the human genome to ensure ≤ 75% homology matches to other genes. Cells were transfected with CTPS2 siRNA (5nM) or negative controls (10nM) using siPORT NeoFX transfection agent (Applied Biosystems) at 50% cell confluence and incubated in serumfree Opti-MEM I medium (Invitrogen) according to the manufacturers' instructions.
Immunoblot Analysis
Adherent cells were grown to 30-50% confluence and then exposed to siRNA or controls at various concentrations and times as indicated. Cells were then harvested and prepared in denaturing lysis buffer for immunoblotting as previously described. 31 The antibody to CTPS2 for immunoblotting was obtained from Sigma, and anti-mouse secondary antibody from Cell Signaling Technology (Danvers, MA).
Inhibition of proliferation assay
Cells in 90µl medium were seeded (3000 cells/well) onto 96-well microtitre plates (Nunc, Rochester, NY). After 24 hours, 10µl of medium containing 5FU or FUDR with graded concentrations ranging from 0.1µM to 1000µM was added to the wells. Effect on cell numbers was assessed using the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) CellTiter 96® (Promega, Madison, WI) assay at 72h post-treatment. The IC 50 was calculated as the drug concentration that inhibited cell proliferation by 50% inhibition compared with vehicle controls as described previously.
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Assessment of Cell Cycle Phase Distribution
Exponentially growing cells were seeded into 25cm argon laser tuned to 488nm and the red fluorescence collected at 630nm. The data was analysed using WinMDI v2.8 and DNA histograms were gated on a display of DNA peak signal against DNA area to exclude clumps or debris.
Apoptosis Measurements
The Cell Death ELISA® (Roche, Mannheim, Germany) kit was used for the measurement of apoptosis. Cells were plated in 96-well plates (3000 cells/well) and the following day were treated with drug or solvent in a volume adjusted to 200μL with 10% FCS/RPMI. After 24 hours, nucleosomes were quantified according to the manufacturer's instructions.
Uridine exposure
Exponentially growing cells were seeded into 25cm for 24 hours as previously described. 23 The media was changed after 24 hours before 5FU addition and MTS assay carried out at 72 hours.
Immunohistochemistry
Four μm sections were cut from tissue array blocks, dewaxed and subjected to automated 
Statistical analysis
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